Bromobenzene → 4-[2-(difluoromethyl)-1H-benzimidazol-1-yl]-6-(morpholin-4-yl)-N-[(1-phenylpiperidin-4-yl)methyl]pyrimidin-2-amine

HRID 1403147Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 1403147
[F:1][CH:2]([F:32])[C:3]1[N:7]([C:8]2[CH:13]=[C:12]([N:14]3[CH2:19][CH2:18][O:17][CH2:16][CH2:15]3)[N:11]=[C:10]([NH:20][CH2:21][CH:22]3[CH2:27][CH2:26][NH:25][CH2:24][CH2:23]3)[N:9]=2)[C:6]2[CH:28]=[CH:29][CH:30]=[CH:31][C:5]=2[N:4]=1.Br[C:34]1[CH:39]=[CH:38][CH:37]=[CH:36][CH:35]=1.C1(P(C2CCCCC2)C2C=CC=CC=2C2C(C(C)C)=CC(C(C)C)=CC=2C(C)C)CCCCC1.P([O-])([O-])([O-])=O.[K+].[K+].[K+]>C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.[Pd].[Pd].COCCOC>[F:32][CH:2]([F:1])[C:3]1[N:7]([C:8]2[CH:13]=[C:12]([N:14]3[CH2:19][CH2:18][O:17][CH2:16][CH2:15]3)[N:11]=[C:10]([NH:20][CH2:21][CH:22]3[CH2:23][CH2:24][N:25]([C:34]4[CH:39]=[CH:38][CH:37]=[CH:36][CH:35]=4)[CH2:26][CH2:27]3)[N:9]=2)[C:6]2[CH:28]=[CH:29][CH:30]=[CH:31][C:5]=2[N:4]=1

Komponenten

7

Edukt 4

HCID 7961BromobenzeneHCID 62657Potassium Phosphate, TribasicHCID 111557942-Dicyclohexylphosphino-2',4',6'-triisoprophylbiphenylHCID 866867774-[2-(difluoromethyl)-1H-benzimidazol-1-yl]-6-morpholin-4-yl-N-(piperidin-4-ylmethyl)pyrimidin-2-amine

Produkt 1

HCID 866867734-[2-(difluoromethyl)-1H-benzimidazol-1-yl]-6-(morpholin-4-yl)-N-[(1-phenylpiperidin-4-yl)methyl]pyrimidin-2-amine

Reagenzien, Katalysatoren, Lösungsmittel 2

HCID 9811564Bis(dibenzylideneacetone)palladiumKatalysatorHCID 80711,2-DimethoxyethaneLösungsmittel

Reaktionsbedingungen

Temperatur
130 °C

Versuchsvorschrift

To a mixture of 4-[2-(difluoromethyl)-1H-benzimidazol-1-yl]-6-morpholin-4-yl-N-(piperidin-4-ylmethyl)pyrimidin-2-amine (50 mg) and 1,2-dimethoxyethane (1 mL) were added bromobenzene (24 μL), tris(dibenzylideneacetone)dipalladium (0) (6.5 mg), dicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine (11 mg), and potassium phosphate (96 mg), and the mixture was stirred in a microwave reactor at 130° C. for 1 hour. The reaction mixture was filtered through celite, and to the filtrate was added silica gel, followed by concentrating under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate) to obtain 4-[2-(difluoromethyl)-1H-benzimidazol-1-yl]-6-(morpholin-4-yl)-N-[(1-phenylpiperidin-4-yl)methyl]pyrimidin-2-amine (39 mg) as a white powder.

Aufarbeitung

  1. filtrationThe reaction mixture was filtered through celite
  2. additionto the filtrate was added silica gel
  3. concentrationby concentrating under reduced pressure
  4. customThe residue was purified by silica gel column chromatography (hexane:ethyl acetate)

Quellen und Nachweise

ORD-Eintrag
ord-cffc402997cb4c589a25c6f48d208e66
Quelldatensatz
uspto-grants-2014_12
Patentnummer
US08912180B2

Notizen zur Reaktion

Wird geladen…